Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?
deadline 2027-04-29
confidence medium
tier 4 evidence
63%PolySignal estimate
Resolution criterion
Yes if, when NCT06641466 is read on clinicaltrials.gov on 29 April 2027, the exact API field protocolSection.statusModule.completionDateStruct.date — Study Completion Date is 30 March 2027 or earlier — that is, the date announced today has not been pushed back. A later recorded date counts as no. If OverallStatus is Terminated, Withdrawn, Suspended, or Unknown status, that counts as no — an unmaintained or halted record is treated as a failure to hold the date, not as a technicality. The value returned by the ClinicalTrials.gov API on the deadline prevails; where the record gives a month without a day, the last day of that month is used. If that exact field is absent or empty on an otherwise existing record, that also counts as no – a missing date is not evidence the deadline will be met, it is treated the same as a halted record.
Verified starting state
As of 3 October 2026: NCT06641466 is registered as RECRUITING, sponsored by Pfizer, with 723 participants. Started 2025-03; announced primary completion 2026-11-29, announced study completion 2027-03-30. Record last updated 2026-07-09. The date under test is 2027-03-30. Source: clinicaltrials.gov/study/NCT06641466
What pushes it up
- Pfizer is a major global sponsor with substantial operational resources to keep trial timelines on track [1].
- The primary completion date is scheduled for November 2026, only two months away from today's date, suggesting recruitment and study activities are near completion [1].
- The record was recently updated in July 2026 maintaining the March 30, 2027 completion target [1].
What pushes it down
- Clinical trials frequently encounter late-stage delays during participant follow-up, data lock, or administrative processing [1].
- Any status change to Terminated, Suspended, Withdrawn, or Unknown, or any pushback past March 30, 2027, results in a negative resolution [1].
What would move this number most
Whether Pfizer encounters delays in trial follow-up or data analysis following the November 2026 primary completion date.
How this number is built
| Deadline | 2027-04-29 |
| Base rate | 60% |
| Best evidence | tier 4 · 0 article(s) used |
| Independent runs | 60 · 65 (spread 5 pts) |
| Confidence | medium |
| Evidence cap | not triggered |
| Last revised | 2026-10-03 14:30 |
| Model | gemini-3.6-flash |